Patient demographics and transplant characteristics by disease
| Patient or transplant factor . | Overall . | ALL∗ . | AML/MDS† . | Other‡ . |
|---|---|---|---|---|
| 163 | 98 | 49 | 16 | |
| Age | ||||
| <10 y (%) | 59 (36.2) | 104 (63.8) | 21 (42.9) | 6 (37.5) |
| ≥10 y (%) | 104 (63.8) | 104 (63.8) | 28 (57.1) | 10 (62.5) |
| Sex | ||||
| Male (%) | 97 (59.5) | 56 (57.1) | 30 (61.2) | 11 (68.7) |
| Female (%) | 66 (40.5) | 42 (42.9) | 19 (38.8) | 5 (31.3) |
| Race and ethnicity | ||||
| White non-Hispanic (%) | 33 (20.2) | 16 (16.4) | 13 (26.6) | 4 (25) |
| White Hispanic (%) | 73 (44.7) | 50 (51) | 17 (34.7) | 6 (37.4) |
| Black (%) | 19 (11.7) | 9 (9.2) | 6 (12.2) | 4 (25) |
| Asian (%) | 19 (11.7) | 12 (12.2) | 6 (12.2) | 1 (6.3) |
| Other or >1 (%) | 19 (11.7) | 11 (11.2) | 7 (14.3) | 1 (6.3) |
| Weight, median (range), kg | 50.6 (6.3-148.4) | 51.9 (6.3-148.4) | 39.6 (6.6-102.1) | 55.9 (8.5-116) |
| Body mass index (per CDC) | ||||
| Not done (<2 y) (%) | 15 (9.2) | 6 (6.1) | 7 (18.4) | 2 (12.5) |
| Underweight (%) | 10 (6.1) | 6 (6.1) | 2 (4.1) | 2 (12.5) |
| Healthy weight (%) | 79 (48.5) | 40 (40.8) | 31 (63.2) | 8 (50) |
| Overweight (%) | 24 (14.7) | 15 (15.3) | 6 (12.2) | 3 (18.7) |
| Obese (%) | 35 (21.5) | 31 (31.7) | 3 (6.1) | 1 (6.3) |
| Remission status | ||||
| Active disease (%) | 9 (5.5) | 1 (1) | 7 (14.3) | 1 (6.3) |
| CR1 (%) | 81 (49.7) | 41 (41.8) | 30 (61.2) | 10 (62.5) |
| CR2 (%) | 58 (35.6) | 42 (42.9) | 12 (24.5) | 4 (25) |
| CR3+ (%) | 15 (9.2) | 14 (14.3) | 0 | 1 (6.3) |
| MRD status | ||||
| Negative by NGS (%) | 54 (33.1) | 65 (39.9) | 4 (8.2) | 4 (25) |
| Negative by flow (%) | 65 (39.9) | 39 (23.9) | 32 (65.3) | 3 (18.7) |
| Positive (by either method) (%) | 39 (23.9) | 5 (3.1) | 12 (24.5) | 5 (31.3) |
| Not done (%) | 5 (3.1) | 0 | 1 (2) | 4 (25) |
| Admission ALC (×109/L), median (range) | 0.95 (0.01-5.11) | 0.88 (0.01-3.12) | 1.05 (0.01-4.51) | 1.23 (0.33-5.11) |
| Donor | ||||
| Father (%) | 51 (31.3) | 26 (26.5) | 20 (40.8) | 5 (31.3) |
| Mother (%) | 56 (34.4) | 34 (34.7) | 17 (34.7) | 5 (31.2) |
| Sibling (full or half) (%) | 52 (31.9) | 36 (36.7) | 10 (20.4) | 6 (37.5) |
| Other§ (%) | 4 (2.4) | 2 (2.1) | 2 (4.1) | 0 |
| CMV serostatus | ||||
| R−/D− (%) | 29 (17.8) | 14 (14.3) | 9 (18.4) | 6 (37.5) |
| R−/D+ (%) | 29 (17.8) | 19 (19.4) | 10 (20.4) | 0 |
| R+/D+ (%) | 79 (48.5) | 51 (52) | 19 (38.8) | 9 (56.2) |
| R+/D− (%) | 26 (15.9) | 14 (14.3) | 11 (22.4) | 1 (6.3) |
| Conditioning | ||||
| Melphalan based (%) | 65 (39.9) | 31 (31.7) | 22 (44.9) | 12 (75) |
| Busulfan based (%) | 31 (19) | 6 (6.1) | 23 (46.9) | 2 (12.5) |
| TBI based (%) | 67 (41.1) | 61 (62.2) | 4 (8.2) | 2 (12.5) |
| ATG timing | ||||
| Proximal (day -10 or closer) (%) | 26 (16) | 15 (15.3) | 10 (20.4) | 1 (6.3) |
| Distal (day -11 or further) (%) | 127 (84) | 83 (84.7) | 39 (79.6) | 15 (93.7) |
| Targeted agent after HCT|| (%) | 19 (11.7) | 9 (9.2) | 5 (10.2) | 5 (31.3) |
| Patient or transplant factor . | Overall . | ALL∗ . | AML/MDS† . | Other‡ . |
|---|---|---|---|---|
| 163 | 98 | 49 | 16 | |
| Age | ||||
| <10 y (%) | 59 (36.2) | 104 (63.8) | 21 (42.9) | 6 (37.5) |
| ≥10 y (%) | 104 (63.8) | 104 (63.8) | 28 (57.1) | 10 (62.5) |
| Sex | ||||
| Male (%) | 97 (59.5) | 56 (57.1) | 30 (61.2) | 11 (68.7) |
| Female (%) | 66 (40.5) | 42 (42.9) | 19 (38.8) | 5 (31.3) |
| Race and ethnicity | ||||
| White non-Hispanic (%) | 33 (20.2) | 16 (16.4) | 13 (26.6) | 4 (25) |
| White Hispanic (%) | 73 (44.7) | 50 (51) | 17 (34.7) | 6 (37.4) |
| Black (%) | 19 (11.7) | 9 (9.2) | 6 (12.2) | 4 (25) |
| Asian (%) | 19 (11.7) | 12 (12.2) | 6 (12.2) | 1 (6.3) |
| Other or >1 (%) | 19 (11.7) | 11 (11.2) | 7 (14.3) | 1 (6.3) |
| Weight, median (range), kg | 50.6 (6.3-148.4) | 51.9 (6.3-148.4) | 39.6 (6.6-102.1) | 55.9 (8.5-116) |
| Body mass index (per CDC) | ||||
| Not done (<2 y) (%) | 15 (9.2) | 6 (6.1) | 7 (18.4) | 2 (12.5) |
| Underweight (%) | 10 (6.1) | 6 (6.1) | 2 (4.1) | 2 (12.5) |
| Healthy weight (%) | 79 (48.5) | 40 (40.8) | 31 (63.2) | 8 (50) |
| Overweight (%) | 24 (14.7) | 15 (15.3) | 6 (12.2) | 3 (18.7) |
| Obese (%) | 35 (21.5) | 31 (31.7) | 3 (6.1) | 1 (6.3) |
| Remission status | ||||
| Active disease (%) | 9 (5.5) | 1 (1) | 7 (14.3) | 1 (6.3) |
| CR1 (%) | 81 (49.7) | 41 (41.8) | 30 (61.2) | 10 (62.5) |
| CR2 (%) | 58 (35.6) | 42 (42.9) | 12 (24.5) | 4 (25) |
| CR3+ (%) | 15 (9.2) | 14 (14.3) | 0 | 1 (6.3) |
| MRD status | ||||
| Negative by NGS (%) | 54 (33.1) | 65 (39.9) | 4 (8.2) | 4 (25) |
| Negative by flow (%) | 65 (39.9) | 39 (23.9) | 32 (65.3) | 3 (18.7) |
| Positive (by either method) (%) | 39 (23.9) | 5 (3.1) | 12 (24.5) | 5 (31.3) |
| Not done (%) | 5 (3.1) | 0 | 1 (2) | 4 (25) |
| Admission ALC (×109/L), median (range) | 0.95 (0.01-5.11) | 0.88 (0.01-3.12) | 1.05 (0.01-4.51) | 1.23 (0.33-5.11) |
| Donor | ||||
| Father (%) | 51 (31.3) | 26 (26.5) | 20 (40.8) | 5 (31.3) |
| Mother (%) | 56 (34.4) | 34 (34.7) | 17 (34.7) | 5 (31.2) |
| Sibling (full or half) (%) | 52 (31.9) | 36 (36.7) | 10 (20.4) | 6 (37.5) |
| Other§ (%) | 4 (2.4) | 2 (2.1) | 2 (4.1) | 0 |
| CMV serostatus | ||||
| R−/D− (%) | 29 (17.8) | 14 (14.3) | 9 (18.4) | 6 (37.5) |
| R−/D+ (%) | 29 (17.8) | 19 (19.4) | 10 (20.4) | 0 |
| R+/D+ (%) | 79 (48.5) | 51 (52) | 19 (38.8) | 9 (56.2) |
| R+/D− (%) | 26 (15.9) | 14 (14.3) | 11 (22.4) | 1 (6.3) |
| Conditioning | ||||
| Melphalan based (%) | 65 (39.9) | 31 (31.7) | 22 (44.9) | 12 (75) |
| Busulfan based (%) | 31 (19) | 6 (6.1) | 23 (46.9) | 2 (12.5) |
| TBI based (%) | 67 (41.1) | 61 (62.2) | 4 (8.2) | 2 (12.5) |
| ATG timing | ||||
| Proximal (day -10 or closer) (%) | 26 (16) | 15 (15.3) | 10 (20.4) | 1 (6.3) |
| Distal (day -11 or further) (%) | 127 (84) | 83 (84.7) | 39 (79.6) | 15 (93.7) |
| Targeted agent after HCT|| (%) | 19 (11.7) | 9 (9.2) | 5 (10.2) | 5 (31.3) |
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CDC, Centers for Disease Control and Prevention; CR, complete remission; MDS, myelodysplastic syndrome; NGS, next-generation sequencing; R+/D−, recipient seropositive and donor seronegative, TBI, total-body irradiation.
Pre-B (n = 80), Ph+ Pre-B (n = 9), and T (n = 9).
AML (n = 32), FLT3-interal tandem duplication AML (n = 5), MDS (n = 7), and secondary MDS/AML (n = 5).
Mixed phenotype acute leukemia (MPAL; n = 5), Ph+ MPAL (n = 3), non-Hodgkin Lymphoma (n = 5), juvenile myelomonocytic leukemia (n = 2), and chronic myelogenous leukemia accelerated phase (n = 1).
Other donors included: uncle (n = 2), cousin (n = 1), and daughter (n = 1).
Targeted agents included dasatinib (n = 13) and sorafenib (n = 6).